Cargando…

Identification of bromodomain-containing protein 4 (BRD4) as a novel marker and epigenetic target in mast cell leukemia

Advanced systemic mastocytosis (SM) is a life-threatening neoplasm characterized by uncontrolled growth and accumulation of neoplastic mast cells (MCs) in various organs and a poor survival. So far, no curative treatment concept has been developed for these patients. We identified the epigenetic rea...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wedeh, Ghaith, Cerny-Reiterer, Sabine, Eisenwort, Gregor, Herrmann, Harald, Blatt, Katharina, Hadzijusufovic, Emir, Sadovnik, Irina, Müllauer, Leonhard, Schwaab, Juliana, Hoffmann, Thomas, Bradner, James E., Radia, Deepti, Sperr, Wolfgang R., Hoermann, Gregor, Reiter, Andreas, Horny, Hans-Peter, Zuber, Johannes, Arock, Michel, Valent, Peter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2015
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4610040/ https://www.ncbi.nlm.nih.gov/pubmed/26055303 http://dx.doi.org/10.1038/leu.2015.138

Ejemplares similares

FLAG-induced remission in a patient with acute mast cell leukemia (MCL) exhibiting t(7;10)(q22;q26) and KIT D816H()
por: Valent, Peter, et al.
Publicado: (2013)

Small-molecule inhibition of BRD4 as a new potent approach to eliminate leukemic stem- and progenitor cells in acute myeloid leukemia (AML)
por: Herrmann, Harald, et al.
Publicado: (2012)

Drug-induced inhibition of phosphorylation of STAT5 overrides drug resistance in neoplastic mast cells
por: Peter, Barbara, et al.
Publicado: (2017)

Identification of a Leukemia-Initiating Stem Cell in Human Mast Cell Leukemia
por: Eisenwort, Gregor, et al.
Publicado: (2019)

BRD4 degradation blocks expression of MYC and multiple forms of stem cell resistance in Ph(+) chronic myeloid leukemia
por: Peter, Barbara, et al.
Publicado: (2022)

CDK4/CDK6 Inhibitors Synergize with Midostaurin, Avapritinib, and Nintedanib in Inducing Growth Inhibition in KIT D816V(+) Neoplastic Mast Cells
por: Schneeweiss-Gleixner, Mathias, et al.
Publicado: (2022)

The KIT and PDGFRA switch-control inhibitor DCC-2618 blocks growth and survival of multiple neoplastic cell types in advanced mastocytosis
por: Schneeweiss, Mathias, et al.
Publicado: (2018)

TKI rotation-induced persistent deep molecular response in multi-resistant blast crisis of Ph+ CML
por: Valent, Peter, et al.
Publicado: (2017)

Engraftment in NSG(SCF) mice correlates with the WHO category and prognosis in systemic mastocytosis
por: Willmann, Michael, et al.
Publicado: (2023)

Long-term treatment with imatinib results in profound mast cell deficiency in Ph+ chronic myeloid leukemia
por: Cerny-Reiterer, Sabine, et al.
Publicado: (2014)

Molecular quantification of tissue disease burden is a new biomarker and independent predictor of survival in mastocytosis
por: Greiner, Georg, et al.
Publicado: (2020)

Preclinical human models and emerging therapeutics for advanced systemic mastocytosis
por: Arock, Michel, et al.
Publicado: (2018)

The pan-BCL-2-blocker obatoclax (GX15-070) and the PI3-kinase/mTOR-inhibitor BEZ235 produce cooperative growth-inhibitory effects in ALL cells
por: Stefanzl, Gabriele, et al.
Publicado: (2017)

Nilotinib-induced vasculopathy: identification of vascular endothelial cells as a primary target site
por: Hadzijusufovic, Emir, et al.
Publicado: (2017)

Phenotyping and Target Expression Profiling of CD34(+)/CD38(−) and CD34(+)/CD38(+) Stem- and Progenitor cells in Acute Lymphoblastic Leukemia
por: Blatt, Katharina, et al.
Publicado: (2018)

Bromodomain-Containing Protein BRD4 Is Hyperphosphorylated in Mitosis
por: Wang, Ranran, et al.
Publicado: (2020)

BRD4: A BET(ter) target for the treatment of AML?
por: Valent, Peter, et al.
Publicado: (2014)

BRD3 and BRD4 BET Bromodomain Proteins Differentially Regulate Skeletal Myogenesis
por: Roberts, Thomas C., et al.
Publicado: (2017)

The Bromodomain Protein Brd4 Insulates Chromatin from DNA Damage Signaling
por: Floyd, Scott R., et al.
Publicado: (2013)

Cell‐based and antibody‐mediated immunotherapies directed against leukemic stem cells in acute myeloid leukemia: Perspectives and open issues
por: Valent, Peter, et al.
Publicado: (2020)

Genetic Regulation of Tryptase Production and Clinical Impact: Hereditary Alpha Tryptasemia, Mastocytosis and Beyond
por: Sprinzl, Bettina, et al.
Publicado: (2021)

Preparation data of the bromodomains BRD3(1), BRD3(2), BRD4(1), and BRPF1B and crystallization of BRD4(1)-inhibitor complexes
por: Hügle, Martin, et al.
Publicado: (2016)

Immunotherapy-Based Targeting and Elimination of Leukemic Stem Cells in AML and CML
por: Valent, Peter, et al.
Publicado: (2019)

Dissecting the Role of BET Bromodomain Proteins BRD2 and BRD4 in Human NK Cell Function
por: Cribbs, Adam P., et al.
Publicado: (2021)

BET Bromodomain Proteins Brd2, Brd3 and Brd4 Selectively Regulate Metabolic Pathways in the Pancreatic β-Cell
por: Deeney, Jude T., et al.
Publicado: (2016)

The bromodomain protein BRD4 regulates splicing during heat shock
por: Hussong, Michelle, et al.
Publicado: (2017)

Transcriptional regulation of autophagy and lysosomal function by bromodomain protein BRD4
por: Sakamaki, Jun-Ichi, et al.
Publicado: (2017)

Bromodomain Protein BRD4 Is Essential for Hair Cell Function and Survival
por: Kannan-Sundhari, Abhiraami, et al.
Publicado: (2020)

Comparative oncology: The paradigmatic example of canine and human mast cell neoplasms
por: Willmann, Michael, et al.
Publicado: (2018)

Evaluation of efficacy of alemtuzumab in 5 patients with aplastic anemia and/or myelodysplastic neoplasm
por: Füreder, Wolfgang, et al.
Publicado: (2016)

Clonal Hematopoiesis with Oncogenic Potential (CHOP): Separation from CHIP and Roads to AML
por: Valent, Peter, et al.
Publicado: (2019)

Selective Small Molecule Induced Degradation of the BET Bromodomain Protein BRD4
por: Zengerle, Michael, et al.
Publicado: (2015)

Bromodomain Protein BRD4 Is a Transcriptional Repressor of Autophagy and Lysosomal Function
por: Sakamaki, Jun-ichi, et al.
Publicado: (2017)

Alchemical Free Energy Methods Applied to Complexes of the First Bromodomain of BRD4
por: Guest, Ellen E., et al.
Publicado: (2022)

Proposed Diagnostic Criteria and Classification of Canine Mast Cell Neoplasms: A Consensus Proposal
por: Willmann, Michael, et al.
Publicado: (2021)

Ludwig Boltzmann Cluster Oncology (LBC ONC): first 10 years and future perspectives
por: Valent, Peter, et al.
Publicado: (2018)

Epigenetic targeting of bromodomain protein BRD4 counteracts cancer cachexia and prolongs survival
por: Segatto, Marco, et al.
Publicado: (2017)

Dicer promotes genome stability via the bromodomain transcriptional co-activator BRD4
por: Gutbrod, M. J., et al.
Publicado: (2022)

Native Mass Spectrometry of BRD4 Bromodomains Linked to a Long Disordered Region
por: Azegami, Nanako, et al.
Publicado: (2022)

Targeting bromodomain-containing protein 4 (BRD4) inhibits MYC expression in colorectal cancer cells
por: Otto, C., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_h47kopgmu2b1le75tsg8d0bj48